Title: Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties
Abstract: Cardiovascular Drug ReviewsVolume 17, Issue 2 p. 115-133 Free Access Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties A. Subissi, A. Subissi Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy.Search for more papers by this authorS. Evangelista, Corresponding Author S. Evangelista Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy.Address correspondence and reprint requests to Dr. Stefano Evangelista, Menarini Ricerche spa, Via Sette Santi 1, 50131 Firenze, Italy. Fax: +5680510. E-mail: [email protected]Search for more papers by this authorA. Giachetti, A. Giachetti Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy.Search for more papers by this author A. Subissi, A. Subissi Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy.Search for more papers by this authorS. Evangelista, Corresponding Author S. Evangelista Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy.Address correspondence and reprint requests to Dr. Stefano Evangelista, Menarini Ricerche spa, Via Sette Santi 1, 50131 Firenze, Italy. Fax: +5680510. E-mail: [email protected]Search for more papers by this authorA. Giachetti, A. Giachetti Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy.Search for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3466.1999.tb00008.xCitations: 46AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Ambrosioni E , Borghi C , Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction . N Engl J Med 1995 ; 332 : 80 – 85 . 2 Anning PB , Grocott RM , Lewis MJ. Effect of sulfhydryl and non sulfhydryl-containing ACE inhibitors on left ventricular relaxation in the isolated guinea pig heart . Endothelium 1997 ; 5 : 265 – 275 . 3 Bagchi D , Iygengar J , Stockwell P , Das DK. Enhanced prostaglandin production in the ischemic reperfused myocardium by captopril linked with its free radical scavenging action . Prostaglandins Leukot Essent Fatty Acids 1989 ; 38 : 145 – 150 . 4 Bennet T , Gardiner SM. Differential effects of various angiotensin-converting enzyme inhibitors . In : JIS Robertson , MG Nicholls , eds. The Renin-Angiotensin System. London : Gower Medical Publishing , 1993 ; 98 : 1 – 16 . 5 Brogelli L , Parenti A , Capaccioli S , et al. The angiotensin converting enzyme inhibitor zofenoprilat prevents endothelial cell apoptosis and promotes coronary angiogenesis "in vitro" . FASEB J 1999 ; 13 : A528 . 6 Brown NJ , Vaughan DE. Angiotensin-converting enzyme inhibitors . Circulation 1998 ; 97 : 1411 – 1420 . 7 Chopra M , Beswick H , Clapperton M , Dargie HJ , Smith HJ , McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors . J Cardiovasc Pharmacol 1992 ; 19 : 330 – 340 . 8 Cushman DW , Wang FL , Fung WC , et al. Comparisons "in vitro", "ex vivo", and "in vivo" of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE) . Br J Clin Pharmacol 1989 ; 28 : 115S – 131S . 9 Cushman DW , Wang FL , Fung WC , Harvey CM , DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs . Am J Hypert 1989 ; 2 : 294 – 306 . 10 De Graef PA , van Gilst WH. The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors . Recent Prog Kinins 1992 ; 38 : 110 – 118 . 11 DeForrest JM , Waldron TL , Krapcho J , et al. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme . J Cardiovasc Pharmacol 1989 ; 13 : 887 – 894 . 12 Del Corso A , Del Monte M , Vilardo PG , et al. Site-specific inactivation of aldose reductase by 4-hydroxynonenal . Arch Biochem Biophys 1998 ; 350 : 245 – 248 . 13 Egan TM , Minta JO , Scrimgeour KG , Cooper JD. Captopril—a potential free radical scavenger: Inhibition of PMN NADPH oxidase . Clin Invest Med 1988 ; 11 : 351 – 356 . 14 Eichler DA , Clough DP. Toxicity testing of antihypertensive drugs . In D Ganten , PJ Mulrow , eds. Pharmacology of Antihypertensive Therapeutics. Berlin : Springer Verlag , 1990 : 783 – 807 . 15 Ferrari R , Cargnoni S , Curello C , Ceconi C , Boraso A , Visioli O. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: Insight into its mechanism of action . J Cardiovasc Pharmacol 1992 ; 20 : 694 – 704 . 16 Freedman AM , Cassidy MM , Weglicki WB. Captopril protects against myocardial injury induced by magnesium deficiency . Hypertension 1991 ; 18 : 141 – 147 . 17 Grover GJ , Sleph PG , Dzwonczyk S , et al. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection . J Pharmacol Exp Ther 1991 ; 257 : 919 – 929 . 18 Koppel H , Holzmann S , Klein W , Horn E , Horn S , Gasser R. KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors . Heart Vessels 1996 ; 11 : 192 – 196 . 19 Kukreja RC , Kontos HA , Hess ML. Captopril and enalaprilat do not scavenge the superoxide anion . Am J Cardiol 1990 ; 65 : 24I – 27I . 20 Liu X , Engelman RM , Ronson JA , Cordis GA , Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors . Cardiovasc Drugs Ther 1992 ; 6 : 437 – 443 . 21 Mak IT , Freedman AM , Dickens BF , Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells . Biochem Pharmacol 1990 ; 40 : 2169 – 2175 . 22 McDonald KM , Carlyle PF , Matthews J , et al. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition . Trans Assoc Am Physic 1990 ; 103 : 229 – 235 . 23 McDonald KM , Garr M , Carlyle F , et al. Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog . Circulation 1994 ; 90 : 3034 – 3036 . 24 Mitchell GF , Pfeffer MA , Finn PV , Pfeffer JM. Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats . Circulation 1996 ; 94 : 2923 – 2929 . 25 Morrison RA , Burkett DE , Arnold ME , D'Arienzo CJ , Weinstein SH. Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs . Pharm Res 1991 ; 8 : 370 – 375 . 26 Morrison RA , Kripalani KJ , Marino AM , et al. Intestinal absorption of captopril and two thioester analogs in rats and dogs . Biopharm Drug Dispos 1997 ; 18 : 25 – 39 . 27 Natoff IL , Attwood MR , Eichler DA , Kogler P , Kleinbloesem CH , van Brummelen P. Cilazapril . Cardiovasc Drug Rev 1990 ; 8 : 1 – 24 . 28 Oosterga M , Voors AA , Buikema H , et al. Functional effects of ACE-inhibitors on angiotensin I conversion in human vasculature . J Am Coll Cardiol ( Suppl A ) 1998 ; 31 : 239A – 240A . 29 Parenti A , Morbidelli L , Brogelli L , Ledda F , Ziche M. Effect of zofenoprilat on coronary venular endothelial cell proliferation . Naunyn Schmiedeberg's Arch Pharmacol ( Suppl 2 ) 1998 ; 358 : A622 . 30 Pinto YM , van Wijngaarden J , van Gilst WH , de Graeff PA , Wesseling H. The effects of short– and long-term treatment with an ACE inhibitor in rats with myocardial infarction . Basic Res Cardiol ( Suppl 1 ) 1991 ; 96 : 165 – 172 . 31 Przyklenk K , Kloner RA. Angiotensin converting enzyme inhibitors improved contractile function of stunned myocardium by different mechanisms of action . Am Heart J 1991 ; 121 : 1319 – 1330 . 32 Przyklenk K , Kloner RA. "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction ? Basic Res Cardiol ( Suppl 1 ) 1993 ; 88 : 139 – 154 . 33 Ranadive SA , Chen AX , Serajuddin ATM. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors . Pharm Res 1992 ; 9 : 1480 – 1486 . 34 Sargent CA , Sleph PG , Dzwonczyk S , et al. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: Possible involvement of the ATP-sensitive potassium channel . J Pharmacol Exp Ther 1993 ; 265 : 609 – 618 . 35 Sun Y , Mendelsohn FAO. Angiotensin converting enzyme inhibitor in heart, kidney, and serum studied "ex vivo" after administration of zofenopril, captopril, and lisinopril . J Cardiovasc Pharmacol 1991 ; 18 : 478 – 486 . 36 Tio AR , de Langen CDJ , de Graeff PA , et al. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig . Cardiovasc Drug Ther 1990 ; 4 : 695 – 704 . 37 van Gilst WH , de Graeff PA , de Leeue MJ , Scholtens E , Wessling H. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilatators . J Cardiovasc Pharmacol 1991 ; 18 : 429 – 436 . 38 van Gilst WH , Scholtens E , de Graeff PA , de Langen CDJ , Wesseling H. Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation . Circulation ( Suppl 1 ) 1988 ; 77 : 24 – 29 . 39 van Wijngaarden J , Pinto YM , van Gilst WH , de Graeff PA , de Langen CDJ , Wesseling H. Converting enzyme inhibition after experimental myocardial infarction in rats: Comparative study between spirapril and zofenopril . Cardiovasc Res 1991 ; 25 : 936 – 942 . 40 van Wijngaarden J , Tio RA , van Gilst WH , de Graeff PA , de Laugen CDJ , Wessling H. Coronary vasodilation induced by captopril and zofenoprilat: Evidence for a prostaglandin-independent mechanism . Naunyn Schumiederbergs Arch Pharmacol 1991 ; 343 : 491 – 495 . 41 Webb RL , Miller D , Traina V , Gomez HJ. Benazepril . Cardiovasc Drug Rev 1990 ; 8 : 89 – 104 . 42 Westlin W , Mullane K. Doses captopril attenuate reperfusion induced myocardial dysfunction by scavenging free radicals ? Circulation ( Suppl 1 ) 1988 ; 77 : I30 – I39 . 43 Zusman RM. Angiotensin-converting enzyme inhibitors: More different than alike? Focus on cardiac performance . Am J Cardiol 1993 ; 72 : 25H – 35H . Citing Literature Volume17, Issue2June 1999Pages 115-133 ReferencesRelatedInformation